Director Li Mingyang -Currently the director and legal representative of China Liver Health (CLH) and responsible for daily administration and project management of the organization. -Once served as the deputy secretary-general of China Pharmaceutical Culture Society and the principal of the preparatory group for CLH and chaired a series of projects related to liver health promotion. 03/2015-12/2015 As the principal in charge, he applied for and implemented the “State Project of Liver & Mental Health Aid for Children”. This project (Item Number: 2015[B021]) was approved by the Ministry of Civil Affairs and funded by Central Financial Support for the year of 2015. With the joint support from 302 Military Hospital, Chinese Society of Hepatology/Science Popularization Branch under Chinese Medical Association, and Peking University Infectious Disease Research Center, CLH carried out a series of medical social work for left-behind children in Jingbian, Dingbian, Hengshan and Suide in Shaanxi Province, including science popularization for liver disease, medical aid and mental rehabilitation. 40 “Liver Health Demonstration Schools” were established, covering over 50,000 students and teachers. 5,100 teenagers received HBV screening and vaccination; 500 poverty-stricken infected children were offered nutrition supplement. CLH also held 200 “Health Social Work Studio”, which served 6000 person-time people. 01/2016-09/2016 As the principal of the preparatory group for CLH and under the guidance of Professor Zhuang Hui (from Peking University Health Science Center, also an academician of Chinese Academy of Engineering) and Professor Wei Lai (the director of Peking University Hepatology Institute and the sixth chairman of Chinese Society of Hepatology under Chinese Medical Association), he applied to the Ministry of Civil Affairs for the establishment of CLH. This national social service agency was approved for registration by the Ministry of Civil Affairs in September 2016. CLH is currently the only national social service organization in the field of liver health in China, with academician Zhuang Hui serving as the honorary chairman, professor Wei Lai serving as the chairman and Li Mingyang serving as the director and legal representative. CLH has established close cooperation relationships with numerous liver disease experts. 11/2016-03/2017 As the principal in charge, he launched the “Liver Health General mobilization, 100 Million Yuan Drug Donation” project jointly with Life Oasis Public Service Centre. 96,000 pieces of Peginterferon alfa-2a Solution for Injection (with the value of over 100 million yuan) were raised from China Primary Health Care Foundation and distributed to 4,000 patients with viral hepatitis nationwide for free. 12/2016-06/2017 As the principal in charge, he launched the “Survey on Status Quo of Discrimination against Hepatitis B” under the guidance of World Health Organization and Chinese Foundation for Hepatitis Prevention and Control. 800 hepatitis B patients from Beijing, Guangzhou, Henan and Shaanxi were included and completed the questionnaires. CLH reviewed the status quo of hepatitis B patients experiencing discrimination and relevant policies, compiled the investigation tool for status quo of discrimination, investigated and analyzed the discrimination status. Peking University People’s Hospital, Nanfang Hospital, Henan Provincial People’s Hospital and Xijing Hospital, etc. participated in the questionnaire survey. 03/2017-06/2017 He provided support for World Health Organization to carry out the “2017 Hepatitis Testing Innovation Challenge”, which strived to popularize the knowledge of hepatitis B and hepatitis C throughout the country, to improve the accessibility of diagnosis and treatment for two types of liver diseases, to correct prejudice and misunderstanding related to hepatitis B and hepatitis C through health education and publicity, and to stop the stigma and discrimination of hepatitis patients. Totally 160 qualified entries were received. The winners were announced at the 2017 China Hepatitis Forum. 09/2017-present As the person in charge of project implementation, he launched the “China Public Welfare Program for Eradication of Hepatitis C” under the guidance of academician Zhuang Hui and professor Wei Lai and with support from WHO Representative Office in China, Peking University Research Center for Infectious Diseases, Chinese Foundation for Hepatitis Prevention and Control, Peking University Institute of Hepatology, Chinese Medical Association Hepatology Branch and Infectious Diseases Branch, Institute of Hepatology in Jilin Province, Health Times under People's Daily, and Hepatitis C Virtual Community. Since the project was launched, the work has been carried out in Yulin City of Shaanxi Province, Jilin Province, Tianjin, Anhui Province, and Hunan Province. CLH has held seminars with local government, health authorities and medical insurance departments to discuss on the policy of including hepatitis C drugs into medical insurance. Extensive cooperation has been developed with local major hospitals to conduct researches targeting at patients, in-hospital and community screening activities, which have achieved initial results. |
关注官方微信 
